Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Epistemonikos ID: 0439dfe07c743c0e2c406cc3d5f62a5f127066d8
First added on: May 09, 2024